

COMPANY OVERVIEW

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen's three drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets.

RECENT NEWS

Nasdaq Grants VistaGen 180-Day Extension to Meet Minimum Bid Price Requirement

Oct 14 2020, 8:30 AM EDT

STOCK OVERVIEW

Symbol	VTGN
Exchange	Nasdaq
Market Cap	58.09m
Last Price	\$0.785
52-Week Range	\$0.2943 - \$1.4862

10/19/2020 04:00 PM EDT

INVESTOR RELATIONS

VistaGen Therapeutics, Inc.
Mark A. McPartland
Vice President, Corporate Development
and Investor Relations
(650) 577-3606
markmcp@vistagen.com

MANAGEMENT TEAM

Shawn K. Singh, J.D.
Chief Executive Officer and Director

H. Ralph Snodgrass, Ph.D.
Founder, President, Chief Scientific Officer
and Director

Mark A. Smith, M.D., Ph.D.
Chief Medical Officer

Jerrold D. Dotson, CPA
Vice President, Chief Financial Officer and
Secretary

Mark A. McPartland
Vice President of Corporate Development

VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue
South San Francisco, CA 94080

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.